Nasdaq-100 Index Shifts Portfolio with Major Reshuffling—Six Additions and Six Removals Ahead

Rekt_Recovery · 2025-12-26T01:49:12+00:00

The Nasdaq-100 has finalized its annual rebalancing, introducing six new companies while removing six others, reflecting changes in market dynamics. This adjustment impacts investor interests and the index's representation of tech and growth sectors.

Rekt_Recovery

2025-12-26 01:49:12

Abstract generation in progress

The Nasdaq has finalized its annual index rebalancing for the Nasdaq-100, with significant portfolio changes set to commence ahead of market opening on December 22, 2025. This reconstitution reflects evolving market dynamics and shifts in company valuations within the benchmark index.

Companies Entering the Index

Six fresh players are joining the Nasdaq-100 ranks. The new additions include Alnylam Pharmaceuticals (ALNY), Ferrovial (FER), Insmed (INSM), Monolithic Power Systems (MPWR), Seagate Technology (STX), and Western Digital (WDC). These inclusions suggest strengthened market positions and enhanced relevance to the index’s composition criteria.

Companies Departing from the Index

Simultaneously, six established members are being delisted from the benchmark. The departing companies are Biogen (BIIB), CDW Corporation (CDW), GlobalFoundries (GFS), Lululemon Athletica (LULU), ON Semiconductor (ON), and The Trade Desk (TTD). Their removal indicates shifting competitive landscapes or adjusted weighting priorities within the index framework.

Market Implications

This annual reconstitution process is a routine but consequential event for the Nasdaq-100, which serves as a barometer for major tech and growth-oriented companies. The rebalancing ensures the index remains aligned with current market realities and investor interests. As these changes take effect, market participants will be monitoring the impact on portfolio performance and sector representation within this influential benchmark gauge.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.